164. Oculocutaneous albinism Clinical trials / Disease details
Clinical trials : 15 / Drugs : 54 - (DrugBank : 34) / Drug target genes : 35 - Drug target pathways : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04193592 (ClinicalTrials.gov) | December 1, 2019 | 6/11/2019 | Efficacy and Safety of Pirfenidone Treatment in HPS-ILD | Pirfenidone in the Treatment of Hermansky Pudlak Syndrome (HPS) - Related Interstitial Lung Disease (ILD) | Hermansky Pudlak Syndrome;Interstitial Lung Disease | Drug: Pirfenidone | Jesse Roman | Genentech, Inc. | Not yet recruiting | 18 Years | 75 Years | All | 50 | Phase 2 | United States;Puerto Rico |
| 2 | NCT00001596 (ClinicalTrials.gov) | September 2005 | 3/11/1999 | Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome | Therapeutic Clinical Trial of Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome | Albinism;Inborn Errors of Metabolism;Oculocutaneous Albinism;Platelet Storage Pool Deficiency;Pulmonary Fibrosis | Drug: Pirfenidone;Drug: Placebo | William Gahl, M.D. | National Human Genome Research Institute (NHGRI) | Completed | 18 Years | N/A | All | 35 | Phase 2 | United States;Puerto Rico |